Pathstone Family Office’s Meridian Bioscience Inc VIVO Stock Holding History

Pathstone Family Office’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38,658	Closed	-$1.28M	–	1567
2022 Q4	$1.28M	Sell	38,658 -690	-2%	-$22.2K	0.01%	679
2022 Q3	$1.24M	Buy	39,348 +20,741	+111%	+$672K	0.01%	638
2022 Q2	$566K	Buy	+18,607	New	+$503K	0.01%	524

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pathstone Family Office's VIVO Position: Q1 2023 in Review

Pathstone Family Office sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 38,658 shares — an estimated $1.28M sold.

Pathstone Family Office first reported a position in VIVO in Q2 2022 and held it in 3 quarters. The position peaked at $1.28M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Pathstone Family Office reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Pathstone Family Office sold 38,658 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.28M.
Pathstone Family Office first reported a position in Meridian Bioscience Inc in Q2 2022 and held it in 3 quarters.
Pathstone Family Office's Meridian Bioscience Inc position peaked at $1.28M in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.